Advertisement
UK markets open in 5 hours 53 minutes
  • NIKKEI 225

    38,713.48
    +639.50 (+1.68%)
     
  • HANG SENG

    18,537.81
    +223.91 (+1.22%)
     
  • CRUDE OIL

    79.68
    +0.42 (+0.53%)
     
  • GOLD FUTURES

    2,353.90
    +13.60 (+0.58%)
     
  • DOW

    39,387.76
    +331.36 (+0.85%)
     
  • Bitcoin GBP

    50,236.17
    +1,180.46 (+2.41%)
     
  • CMC Crypto 200

    1,349.34
    +49.24 (+3.79%)
     
  • NASDAQ Composite

    16,346.26
    +43.46 (+0.27%)
     
  • UK FTSE All Share

    4,558.37
    +14.13 (+0.31%)
     

Exploring Editas Medicine’s Research Pipeline

Exploring Editas Medicine’s Research Pipeline

Editas Medicine’s (EDIT) core capability in genome editing makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology to create molecules that can specifically edit DNA. Ocular diseases and engineered cell medicines are two areas in which Editas’s research programs have matured. Editas Medicine aims to file an investigational new drug application for this program by mid-2018.